Skip to main content
Premium Trial:

Request an Annual Quote

BSI, AstraZeneca Ink Osteoarthritis Biomarker Deal

This article has been updated from a previous version to include BioSystems International's complete name.

 

NEW YORK, Feb. 23 (GenomeWeb News) - BioSystems International and AstraZeneca will collaborate to discover biomarkers for the treatment of osteoarthritis, BioSystems International announced today.

 

Under the agreement, AstraZeneca will provide samples and funding for the research done by BSI, which will retain rights and income from diagnostic applications.

 

AstraZeneca receives a non-exclusive license to use the results for internal R&D activities, including exclusive rights to any new targets. The drug maker will also have a worldwide license to cite or recommend the use of the products developed by BSI as part of the collaboration.

 

Financial details were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more